This effort led to the successful generation of seven novel organoid lines harboring prostate-cancer-specific driver alterations, including ETS-translocations, CHD1 loss, and SPOP and FOXA1 mutations-three of which had not been previously represented in 2D prostate cancer cell line models. This evidence concerns the gene FOXA1 and Familial prostate cancer.